Axsome announces positive results from phase 3 Alzheimer’s disease programme
🔹The company said it is planning to submit a new drug application (NDA) to the US Food and Drug Administration (FDA) for the orally-administered candidate in this indication later this year. 🔹AD is the most common form of dementia, affecting approximately seven million people in the US. The neurodegenerative disease slowly destroys memory and thinking … Read more